Partner with Shionogi

Increasing Patient Options Through Partnering

At the heart of Shionogi’s growth strategy are collaborations, which can include in-licensing, co-promotions, equity investments, divestitures and M&A. Shionogi’s partnerships are key to who we are and how we work. As we continuously look for new product opportunities, we understand the challenges of bringing these products to patients and work tirelessly to meet each challenge head-on. Our team at Shionogi is well resourced and committed to finding the best options that ultimately will improve the lives of our patients around the world.

Our Strengths

Shionogi has established strengths in discovery and drug development, which have led to market leading innovative products in many therapeutic categories over our more than 140-year history. Shionogi has expertise in drug discovery in virology, infectious disease, respiratory and central nervous system (CNS) disorders and through partnerships, we seek to extend our reach to provide the best medicines to patients as demonstrated through our market-leading collaborations. These include:
  • The industry leading ViiV Joint Venture with GSK and Pfizer to treat HIV/AIDS patients
  • A partnership with Duchesnay on Osphena® (ospemifene) in the US and Canada, a product developed by Shionogi for the treatment of dyspareunia
  • An out-licensing deal with BioDelivery Sciences Inc. on Symproic® (naldemedine), a product developed by Shionogi for the treatment of opioid induced constipation for the US market
  • Anti-viral collaboration with Roche in the US and Europe on Xofluza® (baloxavir marboxil), a single use therapy for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours

Therapeutic Areas of Interest

Infectious Diseases/Hospital Based Therapies

Shionogi invites biotechnology and pharmaceutical organizations to present innovative late stage and commercial products, which complement our existing hospital infectious disease business. We seek assets that can offer treatment options in a hospital setting, which could range in profile from anti-infective and anti-fungal products to emergency medicine/critical care inclusive of septic shock, acute respiratory distress syndrome, systemic inflammatory response syndrome, etc. The company will also consider assets that could support transition to an outpatient setting after treatment in the hospital.

Shionogi established a meaningful hospital presence following the 2020 launch of our drug product Fetroja® (cefiderocol) for patients 18 years of age or older with complicated urinary tract infections (c-UTI), hospital-acquired pneumonia or ventilator-associated pneumonia (HAP/VAP) caused by susceptible Gram-negative microorganisms. We hope to partner with companies on assets that can utilize our experienced field-based Fetroja team to bring complementary products to patients in the hospital or possibly out-patient as well, if a particular asset can be used in both settings.

Central Nervous System (CNS)

As noted above, Shionogi has a long track record developing products in CNS, including products for depression, ADHD and pain. In 2020, Shionogi acquired Tetra Therapeutics, which has a leading development compound for the treatment of fragile X syndrome (BPN-14770). In that context, Shionogi is seeking products in many specialty CNS areas including, but not limited to autism, epilepsy, ALS, Parkinson’s associated conditions, and more. It is Shionogi’s intention to utilize these CNS product opportunities to assist in the creation of a stand-alone outpatient business unit, separate from our efforts in the hospital.


In addition to pursuing opportunities in CNS, Shionogi is also looking for assets in respiratory disease or pulmonology, which could be synergistic with our Phase 3 ready compound, sivopixant being developed for the treatment of chronic cough. Shionogi welcomes any asset in this category that addresses a significant unmet medical need for an acute or chronic respiratory or pulmonology condition.

Alliance Partnerships

At Shionogi we take pride in the partnerships established in the US, but we are also eager to form strategic collaborations outside the US that can further our goal of delivering life-saving therapies to patients around the globe. Outside the US, our focus is broader considering both early stage and late stage development opportunities. In the US, our focus is more specific to securing late stage assets that will benefit patients and that will lead to healthier lives in the next few years.

Contact Us

If you or your organization wish to connect with us to discuss an opportunity or to begin a dialogue, please contact Shionogi Business Development at A member of the Shionogi US Business Development team will review your correspondence and respond accordingly in an appropriate timeframe.

Thank you for your interest in partnering with Shionogi. We look forward to hearing from you and potentially working together to supply the best possible medicine to protect the health and wellbeing of the patients we serve.